UNSPSC 51313412: Phenindamine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H19N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 772BQ8KSST, chemically known as 2,3,4,9-tetrahydro-2-methyl-9-phenyl-lh-indeno(2,1-c)pyridine but generally known as phenindamine, which bears US NIH Compound Identifier 11291. European Medicines Agency schedules Phenindamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09764MIG. The term PHENINDAMINE is an International Non-Proprietary Name.

UNSPSC 51313412 Phenindamine is a Commodity code that does not align with the recent state and local opportunities posted under it. The three most recent solicitations tagged to this code—a Seminole County procurement for naloxone and drug deactivation systems, a Texas HHS Request for Information on direct-to-manufacturer prescription programs, and a Minnesota multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—address pharmaceutical supply, distribution, and benefit-program administration rather than phenindamine specifically. The mismatch suggests either a classification error in the source data or that the code is used as a catch-all for pharmaceutical procurement without precise commodity-level specificity. State and local buyers appearing in these records include county health departments (Seminole County), state health agencies (Texas HHS Commission), and multistate cooperative purchasing consortia (MMCAP), reflecting a mix of direct procurement and aggregated purchasing vehicles.

Geographic activity centers on Florida, Texas, and the MMCAP multistate region (Minnesota, Oregon, and participating jurisdictions). Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023—note the date conflict in the source) seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Texas HHS issued an RFI on April 3, 2026 to gauge vendor capability for direct-to-manufacturer prescription contracting outside traditional PBM and wholesaler channels. Minnesota's MMCAP posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with pricing weighted at 75 percent and contract effectiveness July 1, 2026. Vendors should treat this code as unreliable for phenindamine-specific procurement activity and verify actual commodity scope in each RFP or IFB before pursuit.